Although trials of several anti–IL-21 monoclonal antibodies for autoimmune diseases have been conducted (19, 53–55), the only completed phase II trial is of treatment combined with liraglutide in patients newly diagnosed with T1D (ClinicalTrials.gov NCT02443155). Here, IL21 is linked to autoimmune disease.